[
  {
    "ts": null,
    "headline": "Johnson & Johnson’s (JNJ) IMAAVY Demonstrates Superior gMG Control",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 12 stocks that will make you rich in 10 years. On June 23, J&J announced new data from an indirect treatment comparison (ITC) study. The data show that the company’s drug, IMAAVY (nipocalimab-aahu), demonstrated consistent and sustained disease control in patients with generalized myasthenia gravis (gMG) compared […]",
    "url": "https://finnhub.io/api/news?id=ded94b7548170ed642f8cd2be5af8ca60f5621c8fc3db7592fb513fa9d4e8252",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751103684,
      "headline": "Johnson & Johnson’s (JNJ) IMAAVY Demonstrates Superior gMG Control",
      "id": 135623530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 12 stocks that will make you rich in 10 years. On June 23, J&J announced new data from an indirect treatment comparison (ITC) study. The data show that the company’s drug, IMAAVY (nipocalimab-aahu), demonstrated consistent and sustained disease control in patients with generalized myasthenia gravis (gMG) compared […]",
      "url": "https://finnhub.io/api/news?id=ded94b7548170ed642f8cd2be5af8ca60f5621c8fc3db7592fb513fa9d4e8252"
    }
  }
]